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Abstract
Recent studies have shown that Cytomegalovirus (CMV) may be an emerging marker of
immunosenescence. CMV can affect the immune system by directly infecting leukocytes and
hematopoietic cells or by eliciting an expansion of oligoclonal CD8+ T cells/contraction of the
naïve T cell compartment that may reduce the host’s ability to fight other pathogens. To
investigate further CMV-associated changes in immunity, a study was conducted with 1,454
adults (ages 25–91) to determine the association between CMV and reactivation of another latent
herpesvirus, Herpes simplex virus type 1 (HSV-1), as indexed by antibody titers. Elevated
antibody titers to latent HSV-1 were significantly associated with both CMV seropositivity and
high CMV antibody levels. Evaluation by specific age groups (<45, 45–64, and 65+ years old)
revealed that this association was detectable early in life (<45 years of age). Increases in HSV-1
antibodies by age occurred in CMV seropositive individuals but not CMV seronegative subjects.
Within CMV seropositive subjects, increases in HSV-1 antibodies by age were only found in
individuals with low CMV antibody levels as those with high CMV antibodies already exhibited
elevated HSV-1 antibodies. These associations remained significant after accounting for body
mass index, gender, and socioeconomic status. These results suggest that CMV can influence the
immune response to another pathogen and support the concept that CMV may accelerate
immunosenescence.
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INTRODUCTION
Herpesviruses are a clinically important group of viruses that can cause a variety of diseases.
Herpesvirus infections are usually characterized by an acute phase associated with minor
morbidity and mortality followed by a chronic latent phase reflecting a balance between
viral replication and the host immune response. In previously infected (seropositive)
Reprints or correspondence: Dr. Raymond P. Stowe, Microgen Laboratories, 903 Texas Avenue, La Marque, TX 77568,
rpstowe@microgenlabs.com Telephone: (409) 935-6700 FAX: (409) 935-6705.
NIH Public Access
Author Manuscript
J Med Virol. Author manuscript; available in PMC 2013 November 01.
Published in final edited form as:













individuals, antiviral IgG antibodies are always present and are tightly regulated by the
immune system due to control over viral reactivation by cytotoxic T cells [Okano et al.,
1988; Wallace et al., 1999; Babel et al., 2009]. Therefore, levels of herpesvirus antibodies in
healthy individuals are quite stable.
However, a dysfunction of the immune system permits viral reactivation and leads to
increased levels of antiviral antibodies. For instance, age-related declines in cellular
immunity are associated with increased herpesvirus antibodies [Glaser et al., 1985; Musiani
et al., 1988; Weymouth et al., 1990]. In addition to elevated antibodies, increased viral gene
transcription and increased viral DNA were subsequently found in a study of herpesvirus
reactivation in older adults [Stowe et al., 2007]; viral DNA and viral gene transcription in
samples from younger adults in this same study were at or below detectable levels which
corresponded with low antiviral antibody titers.
Cytotoxic T cell function may also be impaired due to stress, resulting in replication and
increased production of antiviral antibodies [Glaser et al., 1987; Glaser et al., 1991; Glaser
et al., 1993; Glaser et al., 1994]. Studies of astronauts have demonstrated increased
herpesvirus antibodies, increased viral gene transcription, and increased viral load as a result
of stress and spaceflight [Mehta et al., 2000, 2004; Pierson et al., 2005; Stowe et al., 2001a,
2001b, 2011]. Importantly, these studies demonstrate a direct correlation between elevated
antiviral antibodies and detection of viral DNA. Thus, levels of antiviral antibodies have
been used as surrogate markers of cellular immune function [McDade et al., 2000; Stowe et
al., 2001a, 2001b; Glaser and Kiecolt-Glaser, 2005; Dowd et al., 2011].
Recent studies have suggested that infection with Cytomegalovirus (CMV), a member of the
herpesvirus family, may be associated with adverse health in the elderly [Bennett et al.,
2011]. CMV infection typically occurs asymptomatically during childhood; by age eleven
approximately 36% of individuals are CMV seropositive and this increases to approximately
60% by age forty [Staras et al., 2006]. In CMV seropositive individuals, a progressive
accumulation of CMV-specific CD8+ T cells occurs over time that results in a significant
portion of the total CD8+ T cell pool in older adults; the frequency of CMV-specific T cells
may reach 25% or more [Gillespie et al., 2000; Khan et al., 2002]. It has been proposed that
such expansions may reduce the immune response to antigenic challenge via a reduction in
the naïve T cell compartment [Pawelec et al., 2004]. Subsequently, it was shown that T cell
responses to Epstein-Barr virus (EBV) were impaired in subjects infected with CMV [Khan
et al., 2004].
Because of the growing interest on age and latent herpesvirus infections [Bennett et al.,
2011; Simanek et al., 2011], samples were collected from a large number of subjects to
examine associations between age, CMV infection, and Herpes simplex virus type 1
(HSV-1) reactivation (indexed by antibody titers). It was hypothesized that CMV
seropositive subjects would have impaired control of HSV-1 leading to reactivation of latent
HSV-1. Furthermore, it was hypothesized that elevated CMV antibodies would positively
correlate with high HSV-1 titers.
METHODS
Subjects
Respondents for this study come from the Texas City Stress and Health Study, an ongoing
assessment of risk, coping, stress, and health in a tri-ethnic community living in Texas City,
TX [Peek et al., 2009]. The sample was generated through a census of Hispanic households
and a simple random sample of non-Hispanic households. Three ethnic strata were selected:
Mexican Americans aged 25–64, Mexican Americans aged 65 and over, and non-Hispanics.
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Housing units (HUs) were selected in each stratum, including all Hispanic HUs and 1 in 8
non-Hispanic HUs. Finally, one adult per household was randomly selected among Mexican
Americans and among non-Hispanics, and all Mexican Americans aged 65 and over. Blood
samples were collected from 1,454 subjects, ages 25–91. All blood samples were drawn
between 8 and 11 a.m. For the measurement of biomarkers, blood was drawn into EDTA
tubes. Plasma was obtained after centrifugation and was stored in 1-mL aliquots at −70°C
until testing. The institutional review board at University of Texas Medical Branch approved
the study protocol, and informed consent was obtained from all participants.
Measurement of anti-HSV-1 and anti-CMV antibodies
Antiviral antibody titers were determined by indirect immunofluorescence (IF) as previously
described [Stowe et al., 2001a; Stowe et al., 2000; Tingate et al., 1997]. Commercially
prepared substrate slides and control sera (Microgen Laboratories, La Marque, TX, and Bion
Enterprises, Park Ridge, IL) were used for determining IgG antibody titers to HSV-1.
Briefly, 30 ul of titrated sera were pipetted onto spot slides and incubated for 30 minutes at
room temperature. After incubation, the spot slides were rinsed for 5 minutes in PBS. The
secondary antibody used was anti-human IgG conjugated with fluorescein isothiocynate.
Evans blue was used as a counterstain. After a second incubation (30 minutes at room
temperature), the slides were washed, lightly blotted, and mounted with mounting medium.
Antibody titers were determined by the highest dilution of serum still able to demonstrate
IF-positive cells. Sera from HSV-1 positive and negative individuals were used as controls.
All specimens were batched analyzed and read blind-coded, and the standard error of the
assay was ±1 dilution.
CMV IgG antibody levels were determined using enzyme immunoassay (Biocheck, Foster
City, CA) according to the manufacturer’s instructions. Briefly, all samples and reagents
were brought to room temperature. Test samples and controls were diluted 1:40 with diluent.
Then, 100 µl of the controls and samples were pipetted into wells. After a 30 minute
incubation period at 37°C, the standards and samples were aspirated from the wells and
washed with buffer using an Embla 96/384 well microplate washer (Molecular Devices,
Menlo Park, CA). One hundred microliters of enzyme conjugate was dispensed into each
well followed by another incubation period. The wells then were washed with buffer, and
100 µl of 3, 3', 5, 5'-tetramethylbenzidine subsequently was added followed by a 15 minute
incubation period. Afterward, 100 µl of stop solution (1N HCL) was added. Absorbance was
read at 450 nm using a SpectraMax Plus plated reader (Molecular Devices). The intra- and
inter-assay coefficient variation ranges of this kit are 4.8% to 5.2% and 6.2% to 8.4%,
respectively.
Statistics
HSV-1 and CMV were examined as both continuous (antibody levels) and categorical
measures (percent seropositive), and “high” CMV where high denotes IgG antibody values
in the top quartile and “high” HSV-1 where high denotes HSV-1 titers ≥1280 [Nazmi et al.,
2010; Stowe et al., 2007; Stowe et al., 2010; Tingate et al., 1997]. The extent to which mean
CMV titer levels, percent of respondents having high CMV antibodies, and percent of
respondents being CMV seropositive varied by age groups (< 45, 45–64, and 65+) was first
assessed. These analyses were duplicated for HSV-1. Second, to determine more specifically
how levels of CMV and HSV antibodies varied by age group, mean antibody levels by 10
year age groupings were examined, with a test for a linear trend. All statistical analysis of
mean HSV-1 and CMV antibodies were performed using ANOVA, and the Chi-square test
was utilized to examine patterns by age group for percent of respondents who were CMV or
HSV seropositive and those who were coded as being high for CMV or HSV IgG
antibodies. Finally, logistic regression was performed to examine the association between
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having high CMV and having high HSV while adjusting for body mass index (BMI),
gender, and socioeconomic status (SES).
RESULTS
The mean age of the 1454 subjects was 48.9 years. Over half (58.4%) were female. Eighty-
four percent of all subjects were CMV seropositive, and greater than 95% of all subjects
were infected with HSV-1. As shown in Table 1, a higher percentage of respondents over
the age of 65 were CMV seropositive (91.2% versus 77.5% for those under age 45, p < .
001), though the age differences for being HSV-1 seropositive were not significant. In
addition, respondents who were 45–64 had a significantly higher mean CMV titer levels
than younger respondents. HSV-1 mean titer levels also varied by age. Respondents younger
than 45 had significantly lower mean HSV-1 titers than those over the age of 45 (p<.05).
Finally, a higher percentage of older respondents in this survey had high levels of both CMV
and HSV-1 titers (p<.001).
To investigate age differences in CMV and HSV-1 antibody levels, additional ANOVAs for
mean titer levels by 10-year age groups were conducted. Figure 1 shows the graph of the
means for CMV and HSV-1 antibody levels. These data indicate that older respondents have
higher levels of both HSV-1 and CMV titers (p < .001 for linear trend). Between the ages of
21–50, there was a steep rise in anti-CMV antibodies. Thereafter, levels of anti-CMV
antibodies remained stable but elevated. Anti-HSV-1 antibodies exhibited a slower rise with
age with titers peaking by age 70.
To show an association between CMV seropositivity and HSV-1 antibody levels, the 1454
subjects were divided into those previously infected with CMV and those who were
seronegative. Mean antibody titers to HSV-1 were significantly higher in those respondents
who were CMV seropositive, and the percentage of subjects with high HSV-1 titers was
significantly higher in CMV seropositive subjects as compared to those who were
seronegative (p<0.05; data not shown).
In the next set of analyses, subjects were subdivided into three age groups to assess
differences in antibody levels to HSV-1 and CMV infection (i.e., seropositivity) by age. For
each age group, CMV seropositive subjects consistently had higher HSV-1 titers than those
who were seronegative (Figure 2). However, this difference was only significant among
those respondents who were <45 years of age (p<.05). When comparing CMV seropositive
subjects across age groups, a higher percentage of respondents who were older had elevated
HSV-1 titers as compared to younger respondents (p<.001); there were no age differences
for those who were CMV seronegative.
Finally, it was determined whether there was an association between high CMV antibody
levels and high HSV-1 titers. There was a significant increase in the percentage of subjects
with high HSV-1 titers in those individuals with high CMV antibodies who were <45 years
of age as compared to those with low CMV antibody levels (Figure 3); no significant
differences were found in the 45–64 and 65+ age groups. When comparing subjects with
low CMV antibodies across age groups, a higher percentage of respondents who were older
had elevated HSV-1 titers as compared to younger respondents (p<.001); there were no age
differences for those who had high CMV antibodies. Notably, these associations remained
significant after accounting for BMI, gender, and SES (data not shown).
DISCUSSION
Exposure to CMV may have important health consequences since recent work suggests that
CMV may reduce the capacity of the immune system to respond to antigenic challenge
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[Khan et al., 2004; Pawelec et al., 2004]. Our goal was to extend these earlier findings by
testing the association between CMV and HSV-1 antibodies in a large sample number that
included a broad range of ages. In the present study, increases in CMV and HSV-1
antibodies were found in older adults as well as an increase in the percentage of subjects
with elevated herpesvirus antibodies indicative of subclinical reactivation. These results are
consistent with prior studies of latent herpesvirus reactivation in the elderly [Glaser et al.,
1985; Musiani et al., 1988; Weymouth et al., 1990; Stowe et al., 2007] which can be
attributed to age-related down-regulation of cellular immunity [Miller, 1991; Effros, 2000;
Effros et al., 2003].
When subjects were grouped according to CMV serostatus, it was found that CMV
seropositive individuals had both greater mean HSV-1 antibody levels as well as a higher
percentage of individuals with high HSV-1 titers. Evaluation among different age groups
showed that the association between CMV seropositivity with HSV-1 antibody levels was
evident early in life as significant differences in HSV-1 titers were found in adults between
the ages of 25–44 but not after age 44. In addition, there was a significant increase in the
percentage of older subjects with high HSV-1 antibodies in CMV seropositive subjects but
not CMV seronegative subjects. These data are consistent with previous studies showing
that CMV infection has a profound impact on the immune system very early in life [Kaye et
al., 2008; Miles et al., 2008; Chidrawar et al., 2009].
When assessing CMV antibody levels as a determinant of high HSV-1 antibodies, it was
again found that there was a significant correlation between high levels of both CMV and
HSV-1 antibodies in individuals <45 years of age. Between age groups, there were no
significant changes in high HSV-1 antibody levels in individuals with high CMV antibodies.
Notably, there was a significant increase in HSV-1 antibodies in older CMV seropositive
adults that did not have high CMV antibody titers. This is in contrast with CMV
seronegative individuals, in which no age-related increase in HSV-1 antibodies was
observed. This is a noteworthy finding which suggests that the immune system of CMV
negative older adults is able to moderate HSV-1 later in life, whereas the immune system of
CMV-infected older adults eventually succumbs to the influence of CMV-induced immune
dysregulation resulting in HSV-1 reactivation. Altogether, these data suggest that
immunosenescence associated with CMV may occur early (<45 years of age) in life.
It is unknown whether the findings related to CMV are solely due to CMV-induced T cell
dysregulation, or if other processes are involved. For instance, inflammation due to cellular
stress (e.g., CMV reactivation, infection with another pathogen, injury, etc.) may activate the
hypothalamic pituitary adrenal axis thereby resulting in HSV-1 replication [Turnbull and
Rivier, 1995; Noisakran et al., 1998; Trzonkowski et al., 2003]. In addition, antigen-specific
CD8+ T cells can produce TNF-α and IFN-γ [Komanduri et al., 2001; Almanzar et al.,
2005], and these cytokines are necessary for the development of CMV-permissive
macrophages [Docke et al., 1994]. Thus, inflammatory cytokines produced by activated T
cells may facilitate additional latent CMV reactivation in macrophages [Soderberg-Naucler,
2006].
These results support and extend prior studies [Khan et al., 2004; Pawelec et al., 2004] and
demonstrate immune dysregulation in CMV infected individuals. Notably, elevated levels of
CMV antibodies have been associated with increased IL-6 and TNF-α levels in older adults
[Trzonkowski et al., 2003; Wikby et al., 2005; Wikby et al., 2006] that may have important
health consequences. Higher CMV antibody titers are also associated with increased CRP
levels [Bennett et al., 2011]. CMV, and more recently EBV, have been implicated in the
development of coronary artery disease [Kendall et al., 1992; Waldman et al., 2008].
Strandberg and coworkers [Strandberg et al., 2003] found that HSV-1 and CMV were
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associated with cognitive impairment in elderly adults with cardiovascular disease. A
subsequent study identified CMV as a predictor of cognitive impairment even after
controlling for numerous covariates including age, education, and health conditions [Aiello
et al., 2006]. In perhaps the most striking study, Wikby et al. [2005] found that the immune
risk phenotype, characterized in part by co-infection with multiple herpesviruses, was
significantly associated with cognitive impairment; the individuals with cognitive
impairment were all deceased at follow-up which was attributed to allostatic overload due in
part to multiple herpesvirus infections. As such, CMV (and other herpesviruses) may trigger
immune dysregulation involved in a number of age-related diseases that may provide a
pathway through which infected subjects may experience poorer health outcomes. Future
studies are needed to elucidate the role of herpesviruses in healthy aging.
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Levels of anti-HSV-1 and anti-CMV antibodies (mean ± SE) by decade (n =1454).
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Relationships between CMV serostatus and percentage of subjects with high HSV-1 titers
within and between age groups.
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Relationships between high CMV antibody levels and percentage of subjects with high
HSV-1 titers within and between age groups.
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Table 1




n 406 580 468
% CMV seropositive 77.5 82.6 91.2 0.001
Mean CMV titera 1.82d 1.91 1.87
% with high CMV antibodiesb 19.4 30.0 26.4 0.001
% HSV-1 seropositive 92.0 98.0 98.0 0.747
Mean HSV-1 titer 795.4e 950.1 1034.9
% with high HSV-1 titersc 18.8 25.5 31.5 0.001
Note: Age-group differences assessed by ANOVA for mean CMV and HSV-1 antibodies and through chi-square for percentage CMV and HSV-1
seropositive and for percentage with high CMV and HSV-1 antibodies.
a
Measured in optical density unit
b
High CMV defined as IgG values in the top quartile for this sample
c
High HSV-1 defined as HSV-1 antibodies ≥1280
d
Significantly different (p<0.05) from 45–64
e
Significantly different (p<0.05) from 45–64 and 65+
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